AxoGen (AXGN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Supermicro plans $7 billion financing to fund AI server orders
Axogen, Inc. Reports 2019 First Quarter Financial Results
May 8, 2019 4:03 PM EDTFirst Quarter Revenue of $23.3 million, representing 35% growth versus first quarter 2018
ALACHUA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the first quarter ended March 31, 2019.
First Quarter 2019 Financial Results and Recent Business Highlights
Revenue of $23.3 million, an increase of 35% compared to first quarter 2018 revenue of $17.3 million Gross margin of 84.0% compared to 84.3% in the... More